Africa: WHO Applauds Agreement to Scale-Up Generic Manufacturing for Access to Long-Acting Injectable Antiretrovirals

[WHO] WHO welcomes the announcement of a new voluntary licensing agreement for patents relating to long acting-cabotegravir (CAB-LA) between ViiV Healthcare and the Medicine Patent Pool. This agreement, will give selected generic manufacturers the opportunity to develop, manufacture and supply generic versions of CAB-LA, in 90 low- and middle-income countries, subject to required regulatory approvals. This is a critical step to support long-term access in the least developed, low-income, lower middle-income and
Source: AllAfrica News: HIV-Aids and STDs - Category: Infectious Diseases Source Type: news